New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis Philip Fowler, 28th August 201829th September 2018 0 shares This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum inhibitory concentrations for a panel of 14 different anti-TB compounds using a specifically designed 96-well plate (called UKMYC5) manufactured by Thermo Fisher. Since the UKMYC5 plate is being used by the CRyPTIC consortium to measure the drug susceptibility profiles of >30,000 clinical TB samples collected worldwide between now and 2020, this manuscript lays the foundations for this large and ambitious tuberculosis research project. It is free to read and download, and the paper briefly mentions my AMyGDA software which we will be using as an independent measuring technique to quality control the measurements made by the laboratory scientists. You can download and AMyGDA software from here. A manuscript is currently under review – you can read a preprint here. The bacterial growth on the UKMYC5 plates are also being classified by a Citizen Science project I have setup, BashTheBug. Share this:Twitter Related antimicrobial resistance clinical microbiology publication tuberculosis
antimicrobial resistance Twitter at #ECCMID 27th April 20175th August 2018 A bit over two years ago I was a guest blogger at the US Biophysical… Share this:Twitter Read More
antimicrobial resistance New preprint: compensatory mutations are associated with increased growth in resistant samples of M. tuberculosis. 22nd June 20238th December 2023 In this preprint, Viki Brunner shows how, using the large CRyPTIC dataset, she can recapitulate… Share this:Twitter Read More
clinical microbiology New preprint: processing SARS-CoV-2 genetics in the cloud 31st January 202431st January 2024 In this preprint, we describe how in July 2022 for two weeks seven sites in… Share this:Twitter Read More